摘要
胰高血糖素样肽1(GLP-1)是由肠L细胞分泌的一种具有葡萄糖依赖性促胰岛素分泌功能的肠促胰素,近年来因其通过促进β细胞增殖与分化、抑制β细胞凋亡、抑制胰高血糖素分泌、抑制胃肠蠕动等方式实现血糖调节效应而成为2型糖尿病发病机制及药物治疗的研究热点。GLP-1受体不仅表达于胰腺,也广泛表达于胰腺外组织,包括胃肠道、心血管系统、中枢神经系统、肺、肾、骨骼、皮肤等,故GLP-1受体激动剂作为基于GLP-1的治疗方法对糖尿病以外疾病的治疗也有越来越多的研究。
Glucagon-like peptide-1 （GLP-1） is an incretin secreted by intestinal L ceils and has a glu-cose-dependent promoting insulin secretion function. In recent years GLP-1 has become the research hotspot of the pathogenesis and drug treatment of type 2 diabetes because of its blood glucose regulation effect through promoting 13 cell proliferation and differentiation, inhibition of 13 cell apoptosis, inhibiting glucagon secretion, and inhibiting gastric motility. GLP-I receptor（ GLP-1 R） is not only expressed in the pancreas, but also widely expressed in other tissues ,including the gastrointestinal tract, cardiovascular system, central nervous system,lung, kidney, bone, skin etc. Therefore,there is a growing number of studies of GLP-1 R agonists, as GLP-1 -based therapies, used for the treatment of diseases besides diabetes.
出处
《医学综述》
2016年第2期309-313,共5页
Medical Recapitulate
基金
国家自然科学基金(81200607)
